Kalvista Pharmaceuticals Inc (KALV)
R&D Expense Growth
-26.21%
Quarterly · Period ending:
KALV R&D Expense Growth
Latest reported-26.21%period ending
Latest reported-26.21%period ending
KALV Quarterly R&D Growth (QoQ) (0.00% → -26.21%)
Latest values, visible window
High-resolution chart · PNG
KALV r&d expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| -26.2111% | |
| 40.3469% | |
| -20.9009% | |
| -4.5875% | |
| 26.1791% | |
| -24.1782% | |
| -37.5892% | |
| 5.4103% | |
| 12.0987% | |
| 17.9894% | |
| -1.1291% | |
| -19.3896% | |
| 19.379% | |
| 10.9863% | |
| -0.5994% | |
| -5.3453% | |
| -2.6598% | |
| 12.4929% | |
| 28.3635% | |
| 15.088% | |
| 30.5595% | |
| -0.5575% | |
| -18.0654% | |
| 17.7122% | |
| -15.5613% | |
| 14.7513% | |
| 1.0634% | |
| -13.0443% | |
| 45.6078% | |
| -2.8695% | |
| -5.7444% | |
| 42.7888% | |
| 28.6719% | |
| 4.288% | |
| 25.4603% | |
| 16.0214% | |
| -10.2725% | |
| 905.7229% | |
| 0% | |
| -90.6002% | |
| -17.0892% | |
| 20.5774% | |
| -21.5586% | |
| 15.428% | |
| 28.7364% | |
| 45.1628% | |
| 19.3143% | |
| 22.807% | |
| 27.6882% | |
| 0% |